

Under the Paperwork Reduction Act of 1995, no persons are

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet

1

of

3

CHIC CENTER 1600/2900

09/780,041
------------

2/9/2001

KLEIN *et al.*

1614

Unknown

UF-10293

[illegible][illegible]

Examiner  
Signature

Anne-Marie Zalk

Date  
Considered

11/1/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

MAR 04 2002

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

## Complete if Known

Application Number	09/780,041
Filing Date	2/9/2001
First Named Inventor	KLEIN et al.
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	UF-10293

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
Amz		KLEIN, RONALD, L. et al., "Neuron-Specific Transduction in the Rat Septohippocampal or Nigrostriatal Pathway by Recombinant Adeno-associated Virus Vectors", <i>Experimental Neurology</i> , 1998, 183-194: 150, Academic Press.	
		KLEIN, RONALD, L. et al., "Long-Term Action of Vector-Derived Nerve Growth Factor or Brain-Derived Neurotrophic Factor on Choline Acetyltransferase and TRK Receptor Levels in the Adult Casal Forebrain", <i>Neuroscience</i> , 1999, 815-821: 90-3, Elsevier Science Ltd., Great Britain.	
		KLEIN, RONALD, L. et al., "Prevention of 6-hydroxydopamine-induced Rotational Behavior by BDNF Somatic Gene Transfer", <i>Brain Research</i> , 1999, 314-320, Elsevier Science.	
		PRICE, DONALD, L. et al., "Genetic Neurodegenerative Diseases: The Human Illness and Transgenic Models", <i>Science</i> , 1998, 1079-1083: 282.	
		HSIAO, KAREN, et al., "Correlative Memory Deficits, A $\beta$ Elevation, and Amyloid Plaques in Transgenic Mice", <i>Science</i> , 1996, 99-10: 274.	
		DUFF, KAREN, et al., "Increased Amyloid- $\beta$ 42(43) in Brains of Mice Expressing Mutant Presenilin 1", <i>Nature</i> , 1996, 710-713: 383.	
		PARIMALA, NACHARAJU, et al., "Accelerated Filament Formation From Tau Protein With Specific FTDP-17 Missense Mutation", <i>FEBS Letters</i> , 1999, 195-199:447, Federation of European Biomedical Societies.	
		POLYMEROPOULOS, MIHAEL, et al., "Mutation in the $\alpha$ -Synuclein Gene Identified in Families with Parkinson's Disease", <i>Science</i> , 1997, 2045-2047: 276.	
		KRUGER, REJKO, et al., "A1a30Pro Mutation in the Gene Encoding $\alpha$ -synuclein in Parkinson's Disease", <i>Nature Genetics</i> , 1998, 106-108:18.	
		ABELIOVICH, ASA, et al., "Mice Lacking $\alpha$ -Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System", <i>Neuron</i> , 2000, 239-252: 25, Cell Press.	
Amz		DICKINSON, DENNIS, W., et al., "Tau and Synuclein and Their Role in Neuropathology", <i>Brain Pathaology</i> , 1999, 657-661: 9.	

Examiner Signature

Anne-Marie Jalk

Date Considered

11/1/02


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

RECEIVED  
MAR 06 2002

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/780,041
				Filing Date	2/9/2001
				First Named Inventor	KLEIN et al.
				Group Art Unit	1614
				Examiner Name	Unknown
				Attorney Docket Number	UF-10293
Sheet	3	of	3		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
Amz		BUXBAUM, JOSEPH, D., et al., "Expression of APP in the Brains of Transgenic Mice Containing the Entire Human APP Gene", <i>Boiochemical and Biophysical Research Communications</i> , 1993, 639-645, 197:2, Academic Press, Inc.	
		HIGGINS, L.S., et al., "Transgenic Mouse Brain Histopathology Resembles Early Alzheimer's Disease", <i>Ann Neurol</i> , 1994, 598-607: 35, American Neurological Association.	
		LAFERLA, FRANK, M., et al., "The Alzheimer's A $\beta$ Peptide Induces Neurodegeneration and Apoptotic Cell Death in Trasgenic Mice", <i>Nature Genetics</i> , 1995, 21-30: 9.	
		LAMB, BRUCE, T., et al., "Introduction and Expression of the 400 Kilobase Precursor Amyloid Protein Gene in Transgenic Mice", <i>Nature Genetics</i> , 1993, 22-30: 5.	
		MORAN, PAULA, M., et al., "Age-related Learning Deficits in Transgenic Mice Expressing the 751-Amino Acid Isoform of Human $\beta$ -amyloid Precursor Protein", <i>Proc. Natl. Acad. Sci.</i> , 1995, 5341-5345: 92.	
		HSIAO, KAREN, K. et al., "Age-related CNS Disorder and Early Death in Transgenic FVB/N Mice Overexpressing Alzheimer Amyloid Precursor Proteins", <i>Neuron</i> , 1995, 1203-1218: 15, Cell Press.	
		NALBANTOGLU, J., et al., "Impaired Learning and LTP in Mice Expressing the Carboxy Terminus of the Alzheimer Amyloid Precursor Protein", <i>Nature</i> , 1997, 500-505: 387.	
		LAMB, BRUCE, T. et al., "Altered Metabolism of Familial Alzheimer's Disease-linked Amyloid Precursor Protein Variants in Yeast Artificial Chromosome Transgenic Mice", <i>Human Molecular Genetics</i> , 1997, 1535-1541, 6: 9, Oxford University Press.	
		KAMMESHEIDT, ANJA, et al., "Deposition of $\beta$ / A4 Immunoreactivity and Neuronal Pathology in Transgenic Mice Expressing the Carboxyl-Terminal Fragment of the Alzheimer Amyloid Precursor in the Brain", <i>Proc. Natl. Acad. Sci.</i> , 1992, 10857-10861: 89, USA.	
		PEEL, ALYSON, L. and KLEIN, RONALD, L., "Adeno-associated Virus Vectors: Activity and Applications in the CNS", <i>Journal of Neuroscience Methods</i> , 2000, 95-104:98, Elsevier Science.	
		KLEIN, RONALD, L. et al., "NGF Gene Transfer to Intrinsic Basal Forebrain Neurons Increases Cholinergic Cell Size and Protects From Age-Related, Spatial Memory Deficits in Middle-Aged Rats", <i>Brain Research</i> , 2000, 144-151: 875, Elsevier Science.	
Amz		KLEIN, RONALD, L. et al., "Adeno-Associated Virus Vector Mediated Gene Transfer to Somatic Cells in the Central Nervous System, <i>Advances in Virus Res.</i> Edited by K. Maramorosch, F.A. Murphy, A.J. Shatkin, J.C. Glorioso, 2000, 507-528: 55, Academic Press, SanDiego.	

Examiner Signature	Anne-Marie Zalk	Date Considered	11/1/02
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231